Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.80 |
| ▸ | PDE5A | O76074 | 5/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.80 |
| ▸ | MEN1 | O00255 | 4/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.80 |
| ▸ | TSHR | P16473 | 4/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.80 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.80 |
| ▸ | GBA1 | P04062 | 3/20 | 0.80 |
| ▸ | USP2 | O75604 | 2/20 | 0.80 |
| ▸ | TP53 | P04637 | 1/20 | 0.80 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.80 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.80 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.80 |
| ▸ | POLB | P06746 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7286130 | 0.90 | PDE5A (1.00) | CYP1A2CYP3A4ALDH1A1CYP2D6PDE5A | |
| SCHEMBL7440031 | 0.88 | PDE5A (0.73) | CYP1A2CYP3A4ALDH1A1CYP2D6PDE5A | |
| SCHEMBL20710514 | 0.86 | CYP1A2 (0.72) | CYP1A2CYP3A4ALDH1A1CYP2D6PDE5A | |
| SCHEMBL7277274 | 0.86 | CYP1A2 (1.00) | CYP1A2CYP3A4ALDH1A1CYP2D6PDE5A | |
| SCHEMBL7279569 | 0.85 | PDE5A (0.77) | CYP1A2CYP3A4ALDH1A1CYP2D6PDE5A | |
| Hydrochloric Acid SCHEMBL7289619 | 0.84 | PDE5A (0.76) | CYP1A2CYP3A4ALDH1A1CYP2D6PDE5A | |
| SCHEMBL7280049 | 0.83 | ALDH1A1 (0.80) | CYP1A2CYP3A4ALDH1A1CYP2D6PDE5A | |
| Hydrochloric Acid SCHEMBL7287894 | 0.83 | ALDH1A1 (0.79) | CYP1A2CYP3A4ALDH1A1CYP2D6PDE5A | |
| SCHEMBL1064854 | 0.82 | CYP1A2 (1.00) | CYP1A2CYP3A4ALDH1A1CYP2D6PDE5A | |
| SCHEMBL7432190 | 0.81 | MAPT (0.74) | CYP1A2CYP3A4ALDH1A1CYP2D6PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0579496-B1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO (JP) | 2001-11-14 | — | — | EP | claimed |
| EP-0579496-A1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-01-19 | — | — | EP | claimed |
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | OSI PHARMACEUTICALS, INC. | 2002-02-28 | — | — | US | disclosed |
| EP-0579496-B1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO (JP) | 2001-11-14 | — | — | EP | disclosed |
| WO-1999059584-A1 | COMBINATION OF PHENTOLAMINE AND CYCLIC GMP PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | SCHERING CORPORATION (US) | 1999-11-25 | — | — | WO | disclosed |
| US-5439895-A | Cardiovascular disorders; inhibitor of thromboxane A2 synthetase and cyclic guanosine 3',5'-monophosphate | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
| US-5436233-A | Nervous system disorders | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-07-25 | — | — | US | disclosed |
| EP-0579496-A1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | VHL, MCL1, NFATC1 | CYP1A2 1452/4885CYP3A4 834/4885ALDH1A1 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.